Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19
Hayder Assad
Current Issues in Pharmacy and Medical Sciences, doi:10.2478/cipms-2022-0020
INTRODUCTION Coronavirus Disease 2019 (COVID-19) is a pandemic disease originating in late 2019 in the People's Republic of China that spread rapidly worldwide [1]. The first reported case in the Najaf governorate, Iraq, was confirmed on February 24, 2020 [2]. As of early June 2021, the global reported cases of COVID-19 have exceeded 170 million with over 3 million deaths [3]. The clinical spectrum of this illness ranges from asymptomatic infection, to acute respiratory distress syndrome (ARDS), circulatory shock, multiorgan failure, and ultimately death [4] . The death rate related to COVID-19 is relatively high -ranging from 5% to 35%, especially in elderly patients and those who have comorbidities [5] . Although different treatment strategies have been explored and used based on emergency approval and evidence-based
ORCID iDs Hayder Assad https://orcid.org/0000-0003-3499-3007
References
Alsharidah, Ayed, Ameen, Alhuraish, Rouheldeen et al., COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study, Int J Infect Dis
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis
Bajwah, Wilcock, Towers, Costantini, Bausewein et al., Managing the supportive care needs of those affected by COVID-19, Eur Respir J
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19 -Final Report, N Engl J Med
Best, Kong, Kaplan-Lewis, Brawley, Baden et al., Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement, J Med Virol
Campos Dm De, Fulco, De Oliveira, Oliveira, SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies, J Evid Based Med
Chappell, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with COVID-19 -preliminary report, N Engl J Med
Chibber, Haq, Ahmed, Andrabi, Singh, Advances in the possible treatment of COVID-19: A review, Eur J Pharmacol
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterol
Kewan, Covut, Mj, Rose, Gopalakrishna et al., Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study, E Clinical Medicine
Lin, Schneeweiss, Tesfaye, Andrea, Liu et al., Pharmacotherapy for hospitalized patients with COVID-19: Treatment patterns by disease severity, Drugs
Mk, Ma, Incidence of the COVID-19 in Iraq -Implications for travellers, Travel Med Infect Dis
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, J Pharm Pharm Sci
Phelan, Katz, Lo, The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance, JAMA
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study,
doi:10.1101/2020.06.24.20133249Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Sahebnasagh, Avan, Saghafi, Mojtahedzadeh, Sadremomtaz et al., Pharmacological treatments of COVID-19, Pharmacol Rep
Salazar, Christensen, Graviss, Nguyen, Castillo et al., Treatment of Coronavirus Disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review, JAMA
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial, Lancet
Watanabe, Kwon, Abeles, Jia, Mehta, Medication use patterns in hospitalized patients with COVID-19 in California During the pandemic, JAMA Netw Open
Who, None
Who, None
Zanasi, Mazzolini, Kantar, A reappraisal of the mucoactive activity and clinical efficacy of bromhexine, Multidiscip Respir Med
